Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caliber Therapeutics has announced a partnership with DSM Biomedical, a division of Royal DSM, the global life sciences and materials sciences company, for the development of a novel drug delivery balloon catheter that can be used to treat vascular diseases such as atherosclerosis.
Subscribe to our email newsletter
The novel devices to be developed by DSM Biomedical and Caliber Therapeutics will enable the controlled and sustained release of drugs to treat vascular diseases such as atherosclerosis.
The partnership will combine proprietary technology from DSM on drug delivery with balloon and catheter technology from Caliber Therapeutics. In addition, DSM Biomedical will grant Caliber Therapeutics a worldwide exclusive license for the use of DSM’s recently launched Trancerta drug delivery platform for the development of this specific application.
The drug delivery platform technology used in this novel drug delivery device is jointly developed by Caliber Therapeutics and DSM. The customized and fine-tuned version of DSM’s Trancerta drug delivery platform seeks to deliver an optimal therapeutic drug dose from Caliber’s targeted angioplasty drug delivery balloon, combining safety and efficacy.
Oded Ben-Joseph, president and CEO of Caliber Therapeutics, said: “We are excited to co-develop a truly transformative and highly versatile platform with our friends at DSM. We believe that this technology will allow for superior drug transfer efficiency into the vessel wall and will open up multiple cardiovascular indications that are currently inaccessible to stenting.”